Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab-RT vs CCRT in LA-SCCHN
NCT02753140Phase 2Unknown
- Start
- Apr 2016
- Primary completion
- Mar 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of cetuximab in squamous cell carcinoma of the head and neck (HNSCC) (2 arms). Primary endpoints: Progression-free survival at 13 months and Incidence of oral mucositis at 3 months. Status: unknown.
02
Drugs
cetuximab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02753140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02753140.